Compare FedEx Corporation (FDX) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FedEx Corporation vs Travere Therapeutics Inc. Common Stock — how do they compare? FedEx Corporation trades at $291.96 (market cap $68.77B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: FedEx Corporation is far larger — about 14.1× Travere Therapeutics Inc. Common Stock's market cap, and FedEx Corporation pays a 1.68% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold FedEx Corporation for 87 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| FDX | TVTX | |
|---|---|---|
Market Cap | $68.77B | $4.88B |
Volume | 914,308 | 1,668,577 |
Sector | Industrials | Health |
52-Week High | $339.35 | $67.52 |
52-Week Low | $189.87 | $26.79 |
Typical Hold Time | 87 Days | 0 Days |
Enterprise Value | $98.41B | $5.01B |
Dividend Yield | 1.68% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FedEx (FDX) trades at $291.28, down 0.33% on the day, with a bearish technical signal. The stock shows solid fundamentals with a P/E of 15.67 and net income margin of 4.68%, though revenue has been flat recently. Recent news includes a $300 million electric truck order and shareholder approval of executive pay. Cash flow is projected to improve significantly in 2026.
The outlook is mixed: strong analyst buy consensus (57%) and a $307.55 price target suggest upside, but technical indicators and rising fuel costs pose near-term risks. Long-term growth depends on execution of cost cuts and capitalizing on industry tailwinds.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About FedEx Corporation
FedEx pioneered overnight delivery in 1973 and remains the world's largest express package provider. In its fiscal 2020 (ended May 2020), FedEx derived 51% of revenue from its express division, 33% from ground, and 10% from freight, its asset-based less-than-truckload shipping segment. The remainder comes from other services, including FedEx Office, which provides document production/shipping, and FedEx Logistics, which provides global forwarding. FedEx acquired Dutch parcel delivery firm TNT Express in 2016. TNT was previously the fourth-largest global parcel delivery provider.
Read more on FDX →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
